SEC	Form	4
-----	------	---

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1 1	lama and Address of Departing Deveop*

1. Name and Address of Reporting Person [*] Pannu Geraldine			2. Issuer Name and Ticker or Trading Symbol <u>Processa Pharmaceuticals, Inc.</u> [PCSA]		ionship of Reporting Person(s) to Issuer all applicable) Director 10% Owner		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/27/2023		Officer (give title below)	Other (specify below)	
C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106		· · · · · · · · · · · · · · · · · · ·	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi X	 Individual or Joint/Group Filing (Check Applicable Lir X Form filed by One Reporting Person Form filed by More than One Reporting Perss 		
(Street) HANOVER	MD	21076					
(City)	(State)	(Zip)	vative Securities Acquired, Disposed of, or Beneficia		ned		

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities Ad Disposed Of (D		4 and 5)	5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount (A) or (D) Price		Price	Transaction(s) (Instr. 3 and 4)		
Common Stock	06/27/2023		М		23,636	A	(1)	53,113	D	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		5. Number of Derivative 5. Securities 4. Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ate	Securities Underlying			9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		
Restricted Stock	\$0	06/27/2023		М			23,636	(1)	(1)	Common Stock	23,636	\$0	0	D	
Restricted Stock	\$0	06/27/2023		Α		101,365		(2)	(2)	Common Stock	101,365	\$0	101,365	D	

Explanation of Responses:

1. Vesting of time-based restricted shares.

2. The Restricted Stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders.

/s/ Geraldine Pannu by Michael B.	07/24/2022	
Kirwan, as Attorney-in-Fact	0//24/2023	
** 0' / / 0	D /	

Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.